Oxford Properties Group and Novaxia have announced a strategic partnership to co-invest in Life Sciences real estate assets in France. The partnership aims to invest over one billion euros by 2024, starting in the Paris region. The French Life Sciences sector has seen significant growth, with venture capital investments in biotech start-ups doubling between 2020 and 2021. This partnership will provide the high-tech infrastructure needed for the sector’s development, including laboratories, research centers, incubators, accelerators, and production facilities. The first phase of investment will focus on the Paris region, which currently faces a shortage of Life Sciences facilities. Additional investments are planned for other French cities like Lyon and Strasbourg.
| Signal | Change | 10y horizon | Driving force |
|---|---|---|---|
| Partnership to invest in Life Sciences real estate | Increase in investment in Life Sciences sector | More advanced and extensive Life Sciences infrastructure | Government prioritization of Life Sciences sector |
| Focus on Paris region for initial investments | Expansion of Life Sciences infrastructure in Paris | Greater availability of labs and research facilities | Shortage of Life Sciences infrastructure in Paris |
| Potential future investments in other French cities | Expansion of Life Sciences infrastructure in cities | Increased access to Life Sciences infrastructure | Need for Life Sciences infrastructure in other cities |
| Collaboration between Oxford Properties and Novaxia | Strengthening of Life Sciences real estate market | Increased investment and development opportunities | Expertise and market knowledge of both companies |
| Oxford Properties’ goal to become a global ecosystem | Creation of global ecosystem for Life Sciences | Incubation, research, and therapy development spaces | Innovation and desire for leadership in Life Sciences |
| Government support for Life Sciences sector in France | Increased government investments and infrastructure | Strengthened Life Sciences industry in France | Need to strengthen health sovereignty in France |
| Focus on developing appropriate infrastructure | Development of specialized Life Sciences facilities | Infrastructure that meets the needs of the industry | Need for specialized infrastructure in Life Sciences |
| Potential for increased international investments | Attraction of international investments in France | Growth of innovative companies in France | Positioning France as a leader in Life Sciences |